YS Biopharma Financials

YS Stock   0.86  0.01  1.15%   
Based on the key measurements obtained from YS Biopharma's financial statements, YS Biopharma Co is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. At this time, YS Biopharma's Total Stockholder Equity is comparatively stable compared to the past year. Net Debt is likely to gain to about 155.2 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 329.1 M in 2024. Key indicators impacting YS Biopharma's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio1.951.81
Significantly Up
Slightly volatile
The financial analysis of YS Biopharma is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for YS Biopharma includes many different criteria found on its balance sheet. For example, investors should never minimize YS Biopharma's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor YS Biopharma's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in YS Biopharma.

Net Income

(175.67 Million)

With this module, you can analyze YS Biopharma financials for your investing period. You should be able to track the changes in YS Biopharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Understanding current and past YS Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of YS Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in YS Biopharma's assets may result in an increase in income on the income statement.
The data published in YS Biopharma's official financial statements usually reflect YS Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of YS Biopharma. For example, before you start analyzing numbers published by YS Biopharma accountants, it's critical to develop an understanding of what YS Biopharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of YS Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, YS Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in YS Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of YS Biopharma Co. Please utilize our Beneish M Score to check the likelihood of YS Biopharma's management manipulating its earnings.

YS Biopharma Stock Summary

YS Biopharma competes with Revelation Biosciences, Cardio Diagnostics, Biodexa Pharmaceticals, ZyVersa Therapeutics, and Sonnet Biotherapeutics. YS Biopharma is entity of United States. It is traded as Stock on NASDAQ exchange.
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIPG8566R102 G9845F109
Business AddressBuilding No 2,
IndustryHealth Care
BenchmarkNYSE Composite
Phone86 10 8920 2086
You should never invest in YS Biopharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of YS Biopharma Stock, because this is throwing your money away. Analyzing the key information contained in YS Biopharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

YS Biopharma Key Financial Ratios

Generally speaking, YS Biopharma's financial ratios allow both analysts and investors to convert raw data from YS Biopharma's financial statements into concise, actionable information that can be used to evaluate the performance of YS Biopharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that YS Biopharma reports annually and quarterly.

YS Biopharma Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining YS Biopharma's current stock value. Our valuation model uses many indicators to compare YS Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across YS Biopharma competition to find correlations between indicators driving YS Biopharma's intrinsic value. More Info.
YS Biopharma Co is rated second in return on equity category among related companies. It is rated first in return on asset category among related companies . At this time, YS Biopharma's Return On Equity is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value YS Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for YS Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the YS Biopharma's earnings, one of the primary drivers of an investment's value.

YS Biopharma Systematic Risk

YS Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. YS Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on YS Biopharma correlated with the market. If Beta is less than 0 YS Biopharma generally moves in the opposite direction as compared to the market. If YS Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one YS Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of YS Biopharma is generally in the same direction as the market. If Beta > 1 YS Biopharma moves generally in the same direction as, but more than the movement of the benchmark.

About YS Biopharma Financials

What exactly are YS Biopharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include YS Biopharma's income statement, its balance sheet, and the statement of cash flows. Potential YS Biopharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although YS Biopharma investors may use each financial statement separately, they are all related. The changes in YS Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on YS Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze YS Biopharma Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as YS Biopharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of YS Biopharma has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if YS Biopharma's financials are consistent with your investment objective using the following steps:
  • Review YS Biopharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand YS Biopharma's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare YS Biopharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if YS Biopharma's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

YS Biopharma Thematic Clasifications

YS Biopharma Co is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in YS Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various YS Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of YS Biopharma growth as a starting point in their analysis.

Price Earnings To Growth Ratio


At this time, YS Biopharma's Price Earnings To Growth Ratio is comparatively stable compared to the past year.

YS Biopharma April 13, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of YS Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of YS Biopharma Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of YS Biopharma Co based on widely used predictive technical indicators. In general, we focus on analyzing YS Biopharma Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build YS Biopharma's daily price indicators and compare them against related drivers.
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for YS Biopharma Stock analysis

When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.